Pursuant to SEBI Circular No. SEBI/HO/ISD/CIR/P/2020/135 dated July 23, 2020, Marksans Pharma has informed that it enclosed reporting of violations related to Code of Conduct framed under SEBI (PIT) Regulations, 2015 by one Designated Person of the Company in the prescribed formats.
The above information is a part of company’s filings submitted to BSE.